Trilogy Capital’s Loxo Oncology, Inc LOXO Stock Holding History

Trilogy Capital’s Portfolio LOXO Stock Details LOXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40	Closed	-$7K	–	644
2018 Q3	$7K	Buy	+40	New	+$6.72K	﹤0.01%	369

Other funds holding LOXO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trilogy Capital's LOXO Position: Q4 2018 in Review

Trilogy Capital sold out of Loxo Oncology, Inc (LOXO) in Q4 2018, closing a stake of 40 shares — an estimated $7K sold.

Trilogy Capital first reported a position in LOXO in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 232 funds tracked by Wall St. Rank hold LOXO as of Q4 2018.

Trilogy Capital reported no remaining Loxo Oncology, Inc position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 40 Loxo Oncology, Inc shares in Q4 2018, an estimated $7K.
Trilogy Capital first reported a position in Loxo Oncology, Inc in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Loxo Oncology, Inc position peaked at $7K in Q3 2018.
232 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.